Severe insulin resistance syndromes

Severe insulin resistance syndromes are a heterogeneous group of rare disorders characterized by profound insulin resistance, substantial metabolic abnormalities, and a variety of clinical manifestations and complications. The etiology of these syndromes may be hereditary or acquired, due to defects in insulin potency and action, cellular responsiveness to insulin, and/or aberrations in adipose tissue function or development. Over the past decades, advances in medical technology, particularly in genomic technologies and genetic analyses, have provided insights into the underlying pathophysiological pathways and facilitated the more precise identification of several of these conditions. However, the exact cellular and molecular mechanisms of insulin resistance have not yet been fully elucidated for all syndromes. Moreover, in clinical practice, many of the syndromes are often misdiagnosed or underdiagnosed. The majority of these disorders associate with an increased risk of severe complications and mortality; thus, early identification and personalized clinical management are of the essence. This Review aims to categorize severe insulin resistance syndromes by disease process, including insulin receptor defects, signaling defects, and lipodystrophies. We also highlight several complex syndromes and emphasize the need to identify patients, investigate underlying disease mechanisms, and develop specific treatment regimens.

Insulin receptor defects

Mutations related to the α subunit of INSR may decrease the number of available mature INSRs or the affinity of INSR for insulin binding. Furthermore, mutations related to β subunit tyrosine kinase domain may impair autophosphorylation, affecting the activation of downstream signaling cascades (30, 31). Genetic causes of insulin resistance from mutations in the INSR gene have been recognized in rare recessively inherited disorders including Donohue syndrome, Rabson-Mendenhall syndrome, and type A insulin resistance syndrome (1).

Donohue syndrome. Donohue syndrome (leprechaunism) is an extremely rare autosomal recessive disease caused by mutations in the INSR gene. It was first described in 1954 (32) and represents the most severe defective insulin signaling syndrome. Diagnosis is based on genetic, biochemical, and clinical characteristics, while functional analyses try to reveal potential genotype/phenotype and structure/phenotype correlations based on the severity of INSR mutations (33, 34). Affected individuals seldom live beyond infancy, with most surviving less than 2 years, mainly due to intercurrent infection (6, 7, 35). While there is no known etiology, in a few cases, decreased immunoglobulin levels, mainly IgG and IgA, with intact cellular and humoral immunity, have been described (36). Normal immunoglobulin concentration, T lymphocytes, and lymphocyte proliferation have also been documented (37, 38). It is possible that impaired polymorphonuclear leukocyte bactericidal activity drives the pathophysiology (38).

Rabson-Mendenhall syndrome. Rabson-Mendenhall syndrome is a rare autosomal recessive disease caused by mutations in the INSR gene (39). Both Rabson-Mendenhall and Donohue syndromes present after birth and associate with growth and developmental defects (perhaps due to the defective mitogenic action of insulin; refs. 6, 40). Patients may present with extremely high insulin levels (41), fasting hypoglycemia (7), and failed responses to endogenous and exogenous insulin, ultimately developing refractory diabetes mellitus, severe ketoacidosis, and microvascular diabetes complications (7, 9, 41). Most individuals develop symptoms early in life but live into their 20s (1, 39). Suspected cases based on the particular clinical manifestations and laboratory findings are confirmed with genetic testing (42).

Type A insulin resistance syndrome. Type A insulin resistance syndrome is also a rare severe insulin resistance syndrome caused by mutations in INSR. Heterozygous and, in some cases, homozygous INSR mutations impair insulin receptor function and signal transduction (43–45). Individuals with type A insulin resistance syndrome can live beyond middle age (34). Diagnosis remains challenging, though early and accurate identification is essential for targeted treatment.

Insulin receptor antibodies

Type B insulin resistance syndrome. Type B insulin resistance syndrome is an infrequent autoimmune disorder caused by polyclonal autoantibodies (usually IgG) against insulin receptors.

Experimental findings suggest that the autoantibodies act biphasically, inducing hypoglycemia in the first (acute) phase while ultimately causing hyperglycemia. The first phase associates with activation of the tyrosine kinase receptor followed by a progressive receptor downregulation and an increased degradation and subsequent reduction in cellular insulin receptors, resulting in insulin resistance and hyperglycemia (46). It has also been proposed that high autoantibody concentrations antagonize (inhibit) the INSR, leading to insulin resistance and hyperglycemia, while low levels partially agonize to elicit hypoglycemia (46–48). Consequently, patients exhibit profound insulin resistance and hyperglycemia, though hypoglycemia may less frequently occur.

Usually, type B insulin resistance syndrome manifests in adulthood with high 10-year mortality risk (49, 50), occurs in middle-aged women, and associates with other autoimmune conditions (such as systemic lupus erythematosus, Sjögren syndrome, and mixed connective tissue disease) or is a manifestation of an underlying malignancy, such as Hodgkin disease and myeloma (49–52).

Lipodystrophies are a heterogeneous group of rare disorders with approximately 1.3–4.7 cases per million (53) and even fewer for genetic lipodystrophies (54). Lipodystrophies are primarily characterized by complete or partial loss of adipose tissue and depletion of lipid storage capacity (55, 56). However, in some cases, specific body areas possess excess adipose tissue (57). In previous decades, evidence has emphasized the critical role of white adipose tissue as an active endocrine organ that efficiently stores excess energy. Based on etiology, lipodystrophy syndromes are either congenital or acquired. According to the extent of adipose tissue deficiency, we have characterized lipodystrophy syndromes as generalized or partial, such that four categories include congenital generalized lipodystrophy, acquired generalized lipodystrophy, congenital partial lipodystrophies, and acquired partial lipodystrophies. Other identified genetic causes (Figure 3) and pathophysiological pathways linked to lipodystrophy challenge the above classification (58).

Figure 3

Molecular pathways implicated in adipogenesis and genes that may lead to the development of lipodystrophy. Several molecular pathways are implicated in the development, differentiation, and apoptosis of adipocytes. The multipotent mesenchymal stem cell (MSC) serves as an adipocyte precursor. Transcription factors promote adipocyte differentiation from mesenchymal stem cells to committed preadipocytes, then to adipocytes. Preadipocytes respond to adipogenic stimuli to initiate cell differentiation to mature adipocytes. Many genes implicated in the adipocyte differentiation process are involved in the potential development of lipodystrophy (red text indicates genes or factors discussed in this Review).

Currently, no formal criteria exist. Despite progress in genetic characterization, a lipodystrophy diagnosis is based on medical history, clinical features, body composition, and metabolic status (55). Lipodystrophic syndromes are often misdiagnosed, or underdiagnosed, because of their scarcity, heterogeneity, and doctors’ perceptions. Notably, many patients, especially those with generalized lipodystrophy, possess low leptin levels. Leptin participates in energy homeostasis, lipid metabolism, and insulin action (59). Despite proposed pathophysiological pathways (60), the exact mechanism by which leptin mediates clinical heterogeneity of the lipodystrophies remains unclear. Although leptin may act peripherally (white adipose tissue, liver, and muscle), affecting appetite, food intake, and lipid and glucose metabolism (60–62), the CNS likely mediates these energy-related effects (63).

The extent of adipose loss and alterations in adiposity is associated with the severity of metabolic derangements and related complications (64, 65). Metabolic disorders, and especially insulin resistance, are present in nearly all types of lipodystrophy. Additionally, more severe clinical presentation usually accompanies more severe insulin resistance. Patients can also develop severe hyperlipidemias, namely hypertriglyceridemia, inadequately controlled diabetes, progressive hepatic disease, and increased metabolic rate (66, 67).

Congenital generalized lipodystrophy

CGL was described initially in 1954 by Berardinelli and five years later by Seip (68, 69). CGL represents rare but clinically prominent disorders with an almost complete lack of adipose presenting from birth (70).

CGL is inherited in an autosomal recessive manner with high prevalence among isolated communities or in cases of parental consanguinity (71). Until now, approximately 300 patients from different ethnic groups have been described (70, 72–76). Patients have a characteristic muscular phenotype due to a near-complete absence of adipose tissue (including subcutaneous and intra-abdominal), usually apparent at birth or during early infancy. Depending on the underlying genetic cause, CGL may spare the supportive adipose tissue such as orbits, palms, soles, and joints (77). Increased insulin levels and a hyperandrogenic state may also contribute to prominent musculature. Other manifestations include acanthosis nigricans, acromegaloid features (70, 73), mental retardation (75), polycystic ovarian syndrome, and hypertrophic cardiomyopathy (78, 79).

Individuals with CGL may develop several metabolic disorders and comorbidities, affecting women more severely (72, 73, 80). Insulin resistance may be present at an early age, even at birth. However, diabetes mellitus often develops in adolescence or early adulthood and is usually refractory to insulin therapy; ketosis is rare. Furthermore, diabetes-related complications, such as nephropathy and retinopathy, constitute a notable cause of morbidity. CGL is also associated with early-onset and progressive severe hypertriglyceridemia, leading to acute pancreatitis, fatty liver disease, and cirrhosis. Notably, individuals with CGL, regardless of age or sex, usually exhibit clinically low leptin levels (60, 81).

There are at least four molecularly distinct CGL types, with types 1 (CGL1) and 2 (CGL2) dominating the cases. AGPAT2 and BSCL2 gene mutations are responsible for CGL1 and CGL2, respectively. AGPAT2 is predominantly expressed in white adipocytes (82) and involved in the acylation process of lysophosphatidic acid to phosphatidic acid, which has a crucial role in triacylglyceride and glycerophospholipid biosynthesis (83). AGPAT2 deficiency associates with impaired signaling of critical elements such as PI3K/AKT and PPARγ, affecting adipogenesis and reducing the levels of stored triglycerides inside the adipose (84). At least 150 cases and 42 AGPAT2 mutations have been published, and the number of related variants has increased over time (85, 86).

Individuals with CGL2 exhibit a more severe disease phenotype demonstrating an intense absence of body fat, including mechanical adipose depots (77). Moreover, the prevalence of diagnosed intellectual impairment is higher in patients with CGL2 (70, 75), who can develop cardiomyopathy even at a young age (78). At least 36 mutations of BSCL2 and 167 individuals with these mutations have been described (85). The BSCL2 gene encodes the seipin protein, which is involved in lipid droplet formation and adipocyte differentiation (74, 87). BSCL2 participates in the biosynthesis of glycerophospholipids and triacylglycerides (83), and mutations may impair adipogenesis, the expression of enzymes (AGPAT2, DGAT2, and lipin-1), and lipogenic transcription factors (PPARγ and CCAAT/enhancer-binding protein-α [C/EBP-α]) (88–90).

Type 3 CGL (CGL3) is linked to CAV1 gene mutations affecting caveolin-1 function. Caveolin-1 constitutes part of the plasma membrane microdomains (caveolae), and is involved in cell migration, polarization, and proliferation (91). Caveolin-1 is also necessary for protein kinase A–mediated (PKA-mediated) phosphorylation of perilipin, which regulates lipolysis (92). Moreover, caveolin-1 loss associates with decreased de novo lipid droplet accumulation and a subsequent white adipose tissue atrophy (92). Caveolin-1 serves functional and structural roles in the biogenesis, accumulation, and metabolism of lipid droplets.

Type 4 CGL (CGL4) associates with mutations identified in the polymerase I and transcript release factor (PTRF) gene, also known as CAVIN-1 (93). Cavin-1 is a peripheral membrane protein and a structural component of caveolae. Moreover, Cavin-1 regulates caveolin-1 and -3 expression (93) and stabilizes and assembles the membrane structure, probably via the cytoskeleton (93, 94). Functionally, Cavin-1 modulates adipocyte differentiation and the expandability of adipose tissue (94, 95). Infants with CGL4 may show progressive body fat loss that can also include facial adipose tissue.

Congenital partial lipodystrophies

Congenital partial lipodystrophies are a group of distinct genetic syndromes characterized by regional lipoatrophy.

Familial partial lipodystrophies. The majority of familial partial lipodystrophy (FPLD) syndromes are inherited in an autosomal dominant manner and demonstrate varying degrees of subcutaneous fat loss. While there are six main FPLD types, other genetic syndromes also display partial lipodystrophy characteristics, resulting in substantial genetic and phenotypic variability (58, 96, 97). The adipose fat loss usually occurs earlier in girls, and is evident during late childhood or puberty (14, 97, 98). Some clinical characteristics and metabolic derangements include insulin resistance, hyperglycemia, diabetes, acanthosis nigricans, hypertriglyceridemia, hepatic steatosis, nonalcoholic steatohepatitis, ectopic fat deposition, hyperandrogenemia, hirsutism, polycystic ovarian syndrome, reproductive dysfunction, osteoporosis, cardiomyopathy, and cardiovascular disease (97).

FPLD1, or Köbberling-type lipodystrophy, follows a polygenic inheritance pattern and is characterized by distal lipoatrophy and visceral adiposity (99, 100). Little is known about the pathological mechanisms.

FPLD2, or Dunnigan-type lipodystrophy, associates with autosomal dominant mutations of the LMNA gene and is the most common FPLD type (more than 500 reported cases; ref. 97). LMNA encodes lamin A and C proteins, which provide structural support to the nuclear envelope. Defects in these proteins may impair interaction with chromatin or other nuclear lamina proteins, leading to adipocyte apoptosis and premature death (101). Prelamin A accumulation may interfere with adipocyte transcription factors or regulators, such as sterol response element–binding protein 1 (SREBP1) and PPARγ, disrupting adipogenesis (101–104). Recent findings indicate that females experience a more severe disease course, due to glucocorticoid receptor GRβ overexpression or increased proinflammatory cytokine levels (105).

FPLD3 results from mutations in PPARG, which regulates adipocyte differentiation and function. FPLD3 is the second most common FPLD (approximately 20 families) and manifests similarly to FPLD1; however, affected patients tend to have more severe hypertriglyceridemia and hypertension (97, 106). Heterozygous mutations may attenuate gene expression or interfere directly with normal gene function (dominant negative) and inhibit adipocyte differentiation.

FPLD4 has been described in four families with autosomal dominant mutations in the PLIN1 gene, encoding perilipin-1 (97). Perilipin-1 is the most abundant phosphoprotein in adipocytes and a principal component of lipid droplet membranes. Perilipin-1 participates in lipid storage and lipolysis by regulating hormone-sensitive lipase (HSL) and adipose tissue triglyceride lipase (ATGL), which catalyze the hydrolysis of diacylglycerol and triacylglycerol into monoacylglycerol and fatty acids (107).

FPLD5 and FPLD6 are autosomal recessive syndromes due to mutations in the cell death inducing DFFA like effector c (CIDEC) and lipase E, hormone sensitive type, (LIPE) genes, respectively. The CIDEC gene is involved in the differentiation of adipocytes. Moreover, CIDEC protein is a main regulator of lipid and glucose metabolism. It has been proposed that CIDEC mutations cause defects in adipocyte differentiation and the inability of lipid droplets to accumulate fat (108, 109). The LIPE gene encodes hormone-sensitive lipase, which associates with adipocyte function and lipid and glucose homeostasis. Pathological mutations of hormone-sensitive lipase may lead to impaired lipolysis, insulin resistance of small adipocytes, and inflammation (110).

Mandibuloacral dysplasia. Mandibuloacral dysplasia (MAD) is a rare autosomal recessive syndrome identified in approximately 40 cases (10, 73). It is characterized by craniofacial, skeletal, and cutaneous abnormalities, including mandibular and clavicular hypoplasia, birdlike face, joint contractures, dental anomalies, acroosteolysis, cutaneous pigmentation, and alopecia. Progeroid features and dysmorphic manifestations may be present at birth and become more prominent with age (98).

Two MAD types reflect the mutations: MAD type A is caused by mutations of the lamin A/C (LMNA) gene, which encodes nuclear lamina proteins. MAD type B associates with zinc metalloprotease (ZMPSTE24) genetic mutations and a more generalized loss of subcutaneous adipose tissue (111, 112). ZMPSTE24 is required for posttranslational proteolytic processing of carboxy-terminal residues of prelamin A to form mature lamin A. Specifically, the prelamin A contains a carboxy-terminal cysteine that is posttranslationally modified (farnesylated) to link with the plasma membrane. Subsequently, ZMPSTE24 catalyzes proteolytic cleavage and facilitates removal of 15 additional carboxy-terminal residues. ZMPSTE24 mutations may lead to the accumulation of the toxic farnesylated form of prelamin A, disrupting nuclear function in several tissues (54). Some patients may experience metabolic complications such as insulin resistance, hyperinsulinemia, diabetes, and hyperlipidemia (113).

SHORT syndrome. SHORT syndrome (short stature; hyperextensibility of joints; ocular depression; Rieger anomaly; teething delay) associates with autosomal dominant mutations of the PI3K p85α regulatory subunit 1 (PIK3R1) gene, which encodes the PIK3R1 protein (regulatory p85a subunit; ref. 114). The p85α subunit connects and stabilizes the p110 catalytic subunit, which determines its activity level (115). Both subunits form the phosphatidylinositol 3-kinase (PI3K) protein, which acts to catalyze the conversion of phosphatidylinositol phosphate 2 (PIP₂) to PIP₃. PIP₃ activates the AKT signaling pathway, which regulates cellular functions including differentiation, cell survival, and insulin’s biological actions (114, 115).

Acquired generalized lipodystrophy

Acquired generalized lipodystrophy (AGL), or Lawrence syndrome, is a rare syndrome (approximately 80 patients) with female dominance (10, 106) and develops in patients with a negative family history, usually during childhood or adolescence (73, 116). Most patients with AGL demonstrate low leptin and markedly reduced adiponectin levels, which may associate with severe insulin resistance and related metabolic complications (117). The pathogenic mechanism is unknown. However, several cases coincided with autoimmune or inflammatory diseases, such as panniculitis, Sjögren syndrome, juvenile-onset dermatomyositis, rheumatoid arthritis, systemic sclerosis, and systemic lupus erythematosus (116, 118, 119). Most recent findings implicate anti-adipocyte antibodies predominantly directed against perilipin-1 (120–122). It has been proposed that autoantibodies, complement activation, and proinflammatory cytokines including TNF-α and IL-1 contribute to AGL by impairing fat uptake, adipocyte differentiation (50, 118, 123), or adipogenesis (124) or increasing receptor-mediated apoptosis of adipocytes/preadipocytes (125, 126).

Acquired partial lipodystrophy

Acquired partial lipodystrophy, also known as Barraquer-Simons syndrome, is one of the most common forms of acquired lipodystrophy (10). It shows a higher prevalence in females and may follow a viral infection (127, 128). Approximately 250 cases, primarily in patients of European descent (57, 73, 129), have been reported manifesting clinical symptoms during childhood or adolescence. The etiology is still uncertain; however, autoimmune-mediated destruction of adipocytes has been proposed. Most patients possess circulating autoantibody known as C3 nephritic factor and low complement component 3 (C3) levels. Importantly, C3 nephritic factor stabilizes C3 convertase enzyme, increasing the half-life of the convertase by blocking C3 degradation, resulting in excessive C3 activation (73). Moreover, low C3 levels, circulating autoantibody called C3 nephritic factor immunoglobulin, and the presence of membranoproliferative glomerulonephritis may coincide, suggesting that inflammation plays a role (73, 130).

Lipodystrophy in HIV patients. The most common type of partial lipodystrophy is HIV-associated lipodystrophy syndrome (HALS), which develops in approximately 40% of patients treated with highly active antiretroviral therapy (HAART), particularly with protease inhibitors and nucleoside analog reverse transcriptase inhibitors. HALS also associates with the duration of HAART treatment (131, 132). The proposed underlying mechanisms involve increased apoptosis, impaired (pre)adipocyte differentiation (133, 134), suppressed adipogenesis (135), and altered expression of adipogenic transcription factors, including PPARγ, SREBP1, C/EBP-α, and C/EBP-β (136). Moreover, HIV infection may inhibit adipocyte differentiation (137), while individual genetic background and inflammation processes may influence the metabolic and clinical manifestations as well as the severity of HALS (138–140). Low leptin concentration associates with reduced subcutaneous adipose tissue, while decreased adipokine levels coincide with excess visceral fat (140, 141).

The prevalence of metabolic syndrome varies, and may associate with HAART treatment duration, chronic inflammation, and the HIV infection itself. While safer HIV medications have decreased the prevalence of HALS (142), patients with HALS are also predisposed to an increased risk of atherosclerosis and cardiovascular disease (143, 144).

Other complex syndromes of severe insulin resistance are described in Supplemental Table 1. Subcutaneous insulin resistance syndrome is a rare condition characterized by profound resistance to the action of subcutaneous insulin while maintaining sensitivity to intravenous insulin, due to increased insulin-degrading activity in the subcutaneous tissue. These patients often experience recurrent episodes of life-threatening diabetic ketoacidosis (145–147).

Patients share common metabolic consequences of severe insulin resistance, such as diabetes, lipid abnormalities, and hepatic derangements, despite their marked phenotypic heterogeneity. Lifestyle modifications, oral and injectable antihyperglycemic medications, insulin, and lipid-lowering medications, along with therapies targeted to reverse or attenuate insulin resistance, constitute our modern treatment armamentarium.

Diet and exercise

Aggressive lifestyle modifications focused on calorie and, when appropriate, weight reduction and increased physical activity are key elements of the therapeutic approach (148–150). Several dietary approaches, including the Mediterranean, likely contribute to maintaining a healthy weight, improving insulin resistance, and lowering inflammatory markers and endothelial dysfunction (151, 152). Moderate-intensity physical activity daily for 30 minutes is beneficial.

Lipoatrophic patients are typically hyperphagic, reportedly secondarily to leptin deficiency. Energy-restricted diets and caloric restriction are anecdotally effective if sustained for long periods of time (55). Most patients should follow diets with the goal of attaining ideal body weight (153), while very-low-fat diets may be appropriate in cases with severe hypertriglyceridemia. Both strength and endurance training are also encouraged (154), except in cases with cardiomyopathy (155).

Insulin

Insulin directly or indirectly affects the function of nearly every tissue in the body. Insulin resistance is defined as a subnormal response to normal insulin concentrations. To overcome insulin resistance, exogenous insulin has been used. Patients with generalized lipodystrophy and patients with INSR mutations typically require higher insulin doses (156, 157). Since high insulin volume may result in discomfort, leakage, and impaired absorption, concentrated insulins (two or five times more concentrated than standard U-100 insulin) should be considered (158, 159).

Insulin-like growth factor-1

Since insulin and IGF-1 mediate their effects through similar tyrosine kinase receptors, and can interchangeably activate the alternate receptor with reduced affinity, IGF-1 is a possible therapeutic agent against insulin resistance. Recombinant human IGF-1 (rhIGF-1) can improve metabolic control in INSR-related severe insulin resistance syndromes and increase life span in patients with Donohue syndrome (160, 161). RhIGF-1 can be administered subcutaneously or via continuous pump infusion (162). RhIGF-1 is thought to exercise its effects on glucose homeostasis mainly by reducing hepatic gluconeogenesis and increasing glucose uptake from peripheral tissues (163). Early treatment with rhIGF-1 typically improves outcomes, although side effects prevented its approval and wide use. Currently available publications are either single case reports or include few patients, rendering a direct comparison of treatment efficacy inconclusive.

Insulin sensitizers

Metformin and thiazolidinediones (TZDs) play a crucial role in severe insulin resistance, improving glucose tolerance, in part by enhancing insulin sensitivity. TZDs or other PPARγ modulators also increase adiponectin levels. Metformin is considered first-line pharmacotherapy for improving insulin sensitivity in patients with lipodystrophies and may also improve fat redistribution in HALS (164). Several reports support the use of TZDs, particularly pioglitazone, to improve the metabolic profile in patients with partial lipodystrophy (165, 166). Only one open-label prospective study tested the troglitazone efficacy (167). Consequently, TZDs need to be used cautiously in patients with generalized lipodystrophy. Similarly, incretin-based therapies including glucagon-like peptide 1 receptor agonists and sodium glucose transporter inhibitors can be used in lipodystrophy, but their efficacy has not been studied systematically.

Lipid-lowering medications

Hyperlipidemia is usually managed with statins, fibrates, and fish oil, rich in omega-3 fatty acids (168, 169). No systemic studies have tested the efficacy of lipid-lowering medications in these patient populations. Combination of fibrates with statins should be used cautiously given the cumulative risk of myopathy and hepatotoxicity. Fibrates and/or long-chain omega-3 fatty acids may be considered for high triglycerides. Additional LDL-cholesterol–lowering medications, such as ezetimibe and PCSK9 (proprotein convertase subtilisin/kexin type 9) antibody inhibitors, are available, though they have not been studied specifically in this patient population. Inclisiran, a small interfering RNA, which may provide sustained LDL reductions, is a promising nonantibody approach that targets PCSK9. The efficacy of inclisiran has been demonstrated in the most recent phase III trials among patients with atherosclerotic cardiovascular disease or its equivalent and elevated LDL level (170). Several liver-specific secreted proteins have been identified as playing a key role in regulating lipid metabolism. Bempedoic acid, an inhibitor of ATP citrate lyase, alone or in combination with statin or ezetimibe, may prove beneficial (171). In 2020, bempedoic acid was approved by the FDA for heterozygous familial hypercholesterolemia. Volanesorsen is a second-generation apolipoprotein C-III antisense oligonucleotide that decreases apolipoprotein C-III, a major triglyceride regulator, and subsequently reduces triglyceride levels (172, 173). The BROADEN Study (174), a randomized, double-blind, placebo-controlled study, recruited patients with partial lipodystrophy and hypertriglyceridemia and will report the effect and safety profile of volanesorsen. Similarly, trials involving angiopoietin-like 3 (ANGPTL3) inhibition via antibodies, such as evinacumab, or antisense oligonucleotides may reveal additional targets for the treatment of hypercholesterolemia in lipodystrophy patient populations (175, 176). Gemcabene is another agent that can enhance the clearance of VLDL-cholesterol, increasing HDL and decreasing hepatic triglyceride synthesis. A clinical study of gemcabene for the management of hypertriglyceridemia and nonalcoholic fatty liver disease in familial partial lipodystrophy patients is ongoing (177).

Etiologic therapeutic strategies

Leptin therapy. Metreleptin, a leptin analog, is the only drug specifically indicated for the treatment of lipodystrophy in the United States (178). In multiple prospective, albeit small and uncontrolled, studies of generalized lipodystrophy, metreleptin treatment suppressed appetite and favored metabolic profiles compatible with reducing, or even discontinuing, antidiabetic medications. Further, nonalcoholic steatohepatitis improved (179–181). In patients taking metreleptin, improved peripheral glucose disposal, hepatic glucose output, and insulin secretion lowered fasting glucose levels (182). Within weeks, triglyceride levels decreased, achieving 60% reduction after one year of treatment (66). Metreleptin has also found off-label use in partial lipodystrophy (183), with possible effectiveness in pediatric patients (184); however, the possibility of developing anti-leptin neutralizing antibodies has prompted the FDA to prevent metreleptin use for any lipodystrophies except complete lipodystrophy (185). While T cell lymphoma has been reported in individuals with acquired lipodystrophy who were treated with metreleptin, it remains unclear whether the cases represented a treatment side effect or a natural history of disease progression (186).

GHRH analog. The growth hormone–releasing hormone (GHRH) analog tesamorelin has FDA approval for use in HALS, in which it improves metabolic abnormalities associated with visceral fat accumulation (187, 188). Tesamorelin is administered as a subcutaneous injection daily. Several randomized clinical trials reported visceral fat reduction during treatment (189, 190), but rapid reaccumulation was noted after discontinuation of therapy. The possibility that tesamorelin worsens glucose intolerance through increased IGF-1 levels warrants caution (191).

Immunosuppresants. Type B insulin resistance is traditionally challenging to manage and has been treated with various forms of immunosuppression with mixed success (192). Malek et al. reported a protocol of rituximab, cyclophosphamide, and pulse steroids (49), which achieved remission in seven patients with type B insulin resistance. However, after about eight months immunosuppressive therapy was stopped and insulin resistance status remained unclear. Complementary strategies to eliminate the culprit antibody may account for the success. Cyclosporin A, azathioprine, intravenous immunoglobulins, and plasmapheresis have also been used with variable effects (193).

Cosmetic surgery

Cosmetic surgery has been effective in correcting hypo- or hypertrophic depots in patients with lipodystrophy, with positive psychological implications (55). However, this approach should ideally be coupled with modifications as outlined above.

This Review has discussed the pathogenesis and features of several severe insulin resistance syndromes and potential therapeutic interventions. Studying these rare conditions has historically opened new pathways in diabetes research and allowed us to gain important insights into insulin’s action and physiology.

All authors contributed to the conception and design of the overall commissioned work. This process was chaired by CSM. All authors were involved in the drafting and revision of the report. AMA and AF led the drafting and editing process. All authors approved the final version for publication and agree to be held accountable for resolving any future questions related to the integrity or accuracy of the work.

View Supplemental data

The authors thank Pooja Bhargava for contributing to research on certain topics discussed herein and for helpful discussions. The authors received no specific funding for this work.

Address correspondence to: Christos S. Mantzoros, ASN-249, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, Massachusetts 02215, USA. Phone: 617.667.8633; Email: cmantzor@bidmc.harvard.edu.

Conflict of interest: CSM reports grants and compensation from Coherus BioSciences, grants from Novo Nordisk, grants from Eisai, compensation from Ansh Labs, and compensation from Aegerion.

Copyright: © 2021, American Society for Clinical Investigation.

Reference information: J Clin Invest. 2021;131(4):e142245.https://doi.org/10.1172/JCI142245.

1. Boucher J, et al. Insulin receptor signaling in normal and insulin-resistant states. Cold Spring Harb Perspect Biol. 2014;6(1):a009191.
   View this article via: PubMed CrossRef Google Scholar
2. Malakar P, et al. Insulin receptor alternative splicing is regulated by insulin signaling and modulates beta cell survival. Sci Rep. 2016;6:31222.
   View this article via: PubMed Google Scholar
3. Belfiore A, et al. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev. 2009;30(6):586–623.
   View this article via: PubMed CrossRef Google Scholar
4. Leibiger B, et al. Selective insulin signaling through A and B insulin receptors regulates transcription of insulin and glucokinase genes in pancreatic beta cells. Mol Cell. 2001;7(3):559–570.
   View this article via: PubMed CrossRef Google Scholar
5. Beale EG. Insulin signaling and insulin resistance. J Investig Med. 2013;61(1):11–14.
   View this article via: PubMed CrossRef Google Scholar
6. Semple RK, et al. Genetic syndromes of severe insulin resistance. Endocr Rev. 2011;32(4):498–514.
   View this article via: PubMed CrossRef Google Scholar
7. Parker VE, Semple RK. Genetics in endocrinology: genetic forms of severe insulin resistance: what endocrinologists should know. Eur J Endocrinol. 2013;169(4):R71–R80.
   View this article via: PubMed CrossRef Google Scholar
8. Cruz PD Jr. , Hud JA Jr. Excess insulin binding to insulin-like growth factor receptors: proposed mechanism for acanthosis nigricans. J Invest Dermatol. 1992;98(6 suppl):82S–85S.
   View this article via: PubMed Google Scholar
9. Tritos NA, Mantzoros CS. Clinical review 97: Syndromes of severe insulin resistance. J Clin Endocrinol Metab. 1998;83(9):3025–3030.
   View this article via: PubMed CrossRef Google Scholar
10. Grunberger G, et al. Syndromes of extreme insulin resistance. In: Poretsky L, eds. Principles of Diabetes Mellitus. Springer; 2017: 1–21.
11. Galvin P, et al. A simple method for quantitation of insulin sensitivity and insulin release from an intravenous glucose tolerance test. Diabet Med. 1992;9(10):921–928.
    View this article via: PubMed CrossRef Google Scholar
12. Katz A, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85(7):2402–2410.
    View this article via: PubMed CrossRef Google Scholar
13. Rager KM, Omar HA. Androgen excess disorders in women: the severe insulin-resistant hyperandrogenic syndrome, HAIR-AN. ScientificWorldJournal. 2006;6:116–121.
    View this article via: PubMed CrossRef Google Scholar
14. Melvin A, et al. Genetic syndromes of severe insulin resistance. Curr Opin Genet Dev. 2018;50:60–67.
    View this article via: PubMed CrossRef Google Scholar
15. Stern JH, et al. Adiponectin, leptin, and fatty acids in the maintenance of metabolic homeostasis through adipose tissue crosstalk. Cell Metab. 2016;23(5):770–784.
    View this article via: PubMed CrossRef Google Scholar
16. Rabe K, et al. Adipokines and insulin resistance. Mol Med. 2008;14(11-12):741–751.
    View this article via: PubMed CrossRef Google Scholar
17. Boutari C, Mantzoros CS. Decreasing lean body mass with age: challenges and opportunities for novel therapies. Endocrinol Metab (Seoul). 2017;32(4):422–425.
    View this article via: PubMed CrossRef Google Scholar
18. Boutari C, Mantzoros CS. Adiponectin and leptin in the diagnosis and therapy of NAFLD. Metabolism. 2020;103:154028.
    View this article via: PubMed Google Scholar
19. Boutari C, et al. Association of adipokines with development and progression of nonalcoholic fatty liver disease. Endocrinol Metab (Seoul). 2018;33(1):33–43.
    View this article via: PubMed CrossRef Google Scholar
20. Kadowaki T, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006;116(7):1784–1792.
    View this article via: JCI PubMed CrossRef Google Scholar
21. Adamczak M, et al. Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens. 2003;16(1):72–75.
    View this article via: PubMed CrossRef Google Scholar
22. Krakoff J, et al. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care. 2003;26(6):1745–1751.
    View this article via: PubMed CrossRef Google Scholar
23. Lindberg S, et al. Adiponectin, type 2 diabetes and cardiovascular risk. Eur J Prev Cardiol. 2015;22(3):276–283.
    View this article via: PubMed CrossRef Google Scholar
24. Pischon T, et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004;291(14):1730–1737.
    View this article via: PubMed CrossRef Google Scholar
25. Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell. 2004;116(2):337–350.
    View this article via: PubMed CrossRef Google Scholar
26. Berglund ED, et al. Direct leptin action on POMC neurons regulates glucose homeostasis and hepatic insulin sensitivity in mice. J Clin Invest. 2012;122(3):1000–1009.
    View this article via: JCI PubMed CrossRef Google Scholar
27. Dardeno TA, et al. Leptin in human physiology and therapeutics. Front Neuroendocrinol. 2010;31(3):377–393.
    View this article via: PubMed CrossRef Google Scholar
28. de Luca C, Olefsky JM. Inflammation and insulin resistance. FEBS Lett. 2008;582(1):97–105.
    View this article via: PubMed CrossRef Google Scholar
29. Jaganathan R, et al. Emerging role of adipocytokines in type 2 diabetes as mediators of insulin resistance and cardiovascular disease. Can J Diabetes. 2018;42(4):446–456.
    View this article via: PubMed CrossRef Google Scholar
30. Hovnik T, et al. Severe progressive obstructive cardiomyopathy and renal tubular dysfunction in Donohue syndrome with decreased insulin receptor autophosphorylation due to a novel INSR mutation. Eur J Pediatr. 2013;172(8):1125–1129.
    View this article via: PubMed CrossRef Google Scholar
31. Escribano O, et al. The role of insulin receptor isoforms in diabetes and its metabolic and vascular complications. J Diabetes Res. 2017;2017:1403206.
    View this article via: PubMed Google Scholar
32. Donohue WL, Uchida I. Leprechaunism: a euphemism for a rare familial disorder. J Pediatr. 1954;45(5):505–519.
    View this article via: PubMed CrossRef Google Scholar
33. Makino H, et al. Insulin receptor gene mutation: a molecular genetical and functional analysis. Cell Signal. 1992;4(4):351–363.
    View this article via: PubMed CrossRef Google Scholar
34. Hosoe J, et al. Structural basis and genotype-phenotype correlations of INSR mutations causing severe insulin resistance. Diabetes. 2017;66(10):2713–2723.
    View this article via: PubMed CrossRef Google Scholar
35. de Bock M, et al. “Donohue syndrome”. J Clin Endocrinol Metab. 2012;97(5):1416–1417.
    View this article via: PubMed CrossRef Google Scholar
36. Gross-Kieselstein E, et al. Leprechaunism (Donohue syndrome). Am J Dis Child. 1973;126(4):500–503.
    View this article via: PubMed Google Scholar
37. Kostopoulou E, et al. Gastrointestinal dysmotility and pancreatic insufficiency in 2 siblings with Donohue syndrome. Pediatr Diabetes. 2017;18(8):839–843.
    View this article via: PubMed CrossRef Google Scholar
38. Sacchi F, et al. Staphylocidal defect of polymorphonuclear leukocytes in a patient with leprechaunism. Eur J Pediatr. 1981;137(1):89–90.
    View this article via: PubMed CrossRef Google Scholar
39. Grasso V, et al. Six cases with severe insulin resistance (SIR) associated with mutations of insulin receptor: is a Bartter-like syndrome a feature of congenital SIR? Acta Diabetol. 2013;50(6):951–957.
    View this article via: PubMed CrossRef Google Scholar
40. Falik Zaccai TC, et al. Two novel mutations identified in familial cases with Donohue syndrome. Mol Genet Genomic Med. 2014;2(1):64–72.
    View this article via: PubMed CrossRef Google Scholar
41. Longo N, et al. Progressive decline in insulin levels in Rabson-Mendenhall syndrome. J Clin Endocrinol Metab. 1999;84(8):2623–2629.
    View this article via: PubMed Google Scholar
42. Takeuchi T, et al. Clinical characteristics of insulin resistance syndromes: a nationwide survey in Japan. J Diabetes Investig. 2020;11(3):603–616.
    View this article via: PubMed CrossRef Google Scholar
43. Musso C, et al. Clinical course of genetic diseases of the insulin receptor (type A and Rabson-Mendenhall syndromes): a 30-year prospective. Medicine (Baltimore). 2004;83(4):209–222.
    View this article via: PubMed CrossRef Google Scholar
44. Iwanishi M, et al. A mutation (Trp1193→Leu1193) in the tyrosine kinase domain of the insulin receptor associated with type A syndrome of insulin resistance. Diabetologia. 1993;36(5):414–422.
    View this article via: PubMed CrossRef Google Scholar
45. Takasawa K, et al. Clinical characteristics of adolescent cases with Type A insulin resistance syndrome caused by heterozygous mutations in the β-subunit of the insulin receptor (INSR) gene. J Diabetes. 2019;11(1):46–54.
    View this article via: PubMed CrossRef Google Scholar
46. Censi S, et al. Insulin autoimmune syndrome: from diagnosis to clinical management. Ann Transl Med. 2018;6(17):335.
    View this article via: PubMed CrossRef Google Scholar
47. Willard DL, et al. Type B insulin resistance syndrome. Curr Opin Endocrinol Diabetes Obes. 2016;23(4):318–323.
    View this article via: PubMed CrossRef Google Scholar
48. Taylor SI, et al. Hypoglycemia associated with antibodies to the insulin receptor. N Engl J Med. 1982;307(23):1422–1426.
    View this article via: PubMed CrossRef Google Scholar
49. Malek R, et al. Treatment of type B insulin resistance: a novel approach to reduce insulin receptor autoantibodies. J Clin Endocrinol Metab. 2010;95(8):3641–3647.
    View this article via: PubMed CrossRef Google Scholar
50. Arioglu E, et al. Clinical course of the syndrome of autoantibodies to the insulin receptor (type B insulin resistance): a 28-year perspective. Medicine (Baltimore). 2002;81(2):87–100.
    View this article via: PubMed CrossRef Google Scholar
51. Cochran E, et al. Other antibodies resulting in diabetes mellitus: type B insulin resistance and insulin autoimmune syndrome. AACE Clin Case Rep. 2016;2(3):e274–e275.
    View this article via: PubMed CrossRef Google Scholar
52. Martins LM, et al. Type B insulin resistance syndrome: a systematic review. Arch Endocrinol Metab. 2020;64(4):337–348.
    View this article via: PubMed Google Scholar
53. Chiquette E, et al. Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges. Diabetes Metab Syndr Obes. 2017;10:375–383.
    View this article via: PubMed CrossRef Google Scholar
54. Garg A. Clinical review#: Lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab. 2011;96(11):3313–3325.
    View this article via: PubMed CrossRef Google Scholar
55. Brown RJ, et al. The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline. J Clin Endocrinol Metab. 2016;101(12):4500–4511.
    View this article via: PubMed CrossRef Google Scholar
56. Robbins AL, Savage DB. The genetics of lipid storage and human lipodystrophies. Trends Mol Med. 2015;21(7):433–438.
    View this article via: PubMed CrossRef Google Scholar
57. Fiorenza CG, et al. Lipodystrophy: pathophysiology and advances in treatment. Nat Rev Endocrinol. 2011;7(3):137–150.
    View this article via: PubMed CrossRef Google Scholar
58. Araújo-Vilar D, Santini F. Diagnosis and treatment of lipodystrophy: a step-by-step approach. J Endocrinol Invest. 2019;42(1):61–73.
    View this article via: PubMed CrossRef Google Scholar
59. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89(6):2548–2556.
    View this article via: PubMed CrossRef Google Scholar
60. Moon HS, et al. Leptin’s role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals. Endocr Rev. 2013;34(3):377–412.
    View this article via: PubMed CrossRef Google Scholar
61. Farooqi IS, et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest. 2002;110(8):1093–1103.
    View this article via: JCI PubMed CrossRef Google Scholar
62. Gallardo N, et al. Tissue-specific effects of central leptin on the expression of genes involved in lipid metabolism in liver and white adipose tissue. Endocrinology. 2007;148(12):5604–5610.
    View this article via: PubMed CrossRef Google Scholar
63. Prieur X, et al. Leptin regulates peripheral lipid metabolism primarily through central effects on food intake. Endocrinology. 2008;149(11):5432–5439.
    View this article via: PubMed CrossRef Google Scholar
64. Cortés VA, Fernández-Galilea M. Lipodystrophies: adipose tissue disorders with severe metabolic implications. J Physiol Biochem. 2015;71(3):471–478.
    View this article via: PubMed CrossRef Google Scholar
65. Hussain I, et al. Lipodystrophies, dyslipidaemias and atherosclerotic cardiovascular disease. Pathology. 2019;51(2):202–212.
    View this article via: PubMed CrossRef Google Scholar
66. Diker-Cohen T, et al. Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin. J Clin Endocrinol Metab. 2015;100(5):1802–1810.
    View this article via: PubMed CrossRef Google Scholar
67. Polyzos SA, et al. Fatty liver in lipodystrophy: a review with a focus on therapeutic perspectives of adiponectin and/or leptin replacement. Metabolism. 2019;96:66–82.
    View this article via: PubMed CrossRef Google Scholar
68. Berardinelli W. An undiagnosed endocrinometabolic syndrome: report of 2 cases. J Clin Endocrinol Metab. 1954;14(2):193–204.
    View this article via: PubMed CrossRef Google Scholar
69. Seip M. Lipodystrophy and gigantism with associated endocrine manifestations. A new diencephalic syndrome? Acta Paediatr. 1959;48:555–574.
    View this article via: PubMed Google Scholar
70. Agarwal AK, et al. Phenotypic and genetic heterogeneity in congenital generalized lipodystrophy. J Clin Endocrinol Metab. 2003;88(10):4840–4847.
    View this article via: PubMed CrossRef Google Scholar
71. Magré J, et al. Prevalence of mutations in AGPAT2 among human lipodystrophies. Diabetes. 2003;52(6):1573–1578.
    View this article via: PubMed CrossRef Google Scholar
72. Premkumar A, et al. Lipoatrophic-lipodystrophic syndromes: the spectrum of findings on MR imaging. AJR Am J Roentgenol. 2002;178(2):311–318.
    View this article via: PubMed CrossRef Google Scholar
73. Garg A. Acquired and inherited lipodystrophies. N Engl J Med. 2004;350(12):1220–1234.
    View this article via: PubMed CrossRef Google Scholar
74. Szymanski KM, et al. The lipodystrophy protein seipin is found at endoplasmic reticulum lipid droplet junctions and is important for droplet morphology. Proc Natl Acad Sci U S A. 2007;104(52):20890–20895.
    View this article via: PubMed CrossRef Google Scholar
75. Van Maldergem L, et al. Genotype-phenotype relationships in Berardinelli-Seip congenital lipodystrophy. J Med Genet. 2002;39(10):722–733.
    View this article via: PubMed CrossRef Google Scholar
76. Patni N, Garg A. Congenital generalized lipodystrophies—new insights into metabolic dysfunction. Nat Rev Endocrinol. 2015;11(9):522–534.
    View this article via: PubMed CrossRef Google Scholar
77. Simha V, Garg A. Phenotypic heterogeneity in body fat distribution in patients with congenital generalized lipodystrophy caused by mutations in the AGPAT2 or seipin genes. J Clin Endocrinol Metab. 2003;88(11):5433–5437.
    View this article via: PubMed CrossRef Google Scholar
78. Bhayana S, et al. Cardiomyopathy in congenital complete lipodystrophy. Clin Genet. 2002;61(4):283–287.
    View this article via: PubMed CrossRef Google Scholar
79. Rheuban KS, et al. Hypertrophic cardiomyopathy in total lipodystrophy. J Pediatr. 1986;109(2):301–302.
    View this article via: PubMed CrossRef Google Scholar
80. Akinci B, et al. Phenotypic and genetic characteristics of lipodystrophy: pathophysiology, metabolic abnormalities, and comorbidities. Curr Diab Rep. 2018;18(12):143.
    View this article via: PubMed CrossRef Google Scholar
81. Lima JG, et al. Clinical and laboratory data of a large series of patients with congenital generalized lipodystrophy. Diabetol Metab Syndr. 2016;8:23.
    View this article via: PubMed Google Scholar
82. Shindou H, et al. Recent progress on acyl CoA: lysophospholipid acyltransferase research. J Lipid Res. 2009;50(suppl):S46–S51.
    View this article via: PubMed Google Scholar
83. Leung DW. The structure and functions of human lysophosphatidic acid acyltransferases. Front Biosci. 2001;6:D944–D953.
    View this article via: PubMed Google Scholar
84. Subauste AR, et al. Alterations in lipid signaling underlie lipodystrophy secondary to AGPAT2 mutations. Diabetes. 2012;61(11):2922–2931.
    View this article via: PubMed CrossRef Google Scholar
85. Craveiro Sarmento AS, et al. The worldwide mutational landscape of Berardinelli-Seip congenital lipodystrophy. Mutat Res. 2019;781:30–52.
    View this article via: PubMed CrossRef Google Scholar
86. Ceccarini G, et al. Congenital generalized lipoatrophy (berardinelli-seip syndrome) type 1: description of novel AGPAT2 homozygous variants showing the highly heterogeneous presentation of the disease. Front Endocrinol (Lausanne). 2020;11:39.
    View this article via: PubMed Google Scholar
87. Cartwright BR, et al. Seipin performs dissectible functions in promoting lipid droplet biogenesis and regulating droplet morphology. Mol Biol Cell. 2015;26(4):726–739.
    View this article via: PubMed CrossRef Google Scholar
88. Talukder MM, et al. Seipin oligomers can interact directly with AGPAT2 and Lipin 1, physically scaffolding critical regulators of adipogenesis. Mol Metab. 2015;4(3):199–209.
    View this article via: PubMed CrossRef Google Scholar
89. Payne VA, et al. The human lipodystrophy gene BSCL2/seipin may be essential for normal adipocyte differentiation. Diabetes. 2008;57(8):2055–2060.
    View this article via: PubMed CrossRef Google Scholar
90. Chen W, et al. The human lipodystrophy gene product Berardinelli-Seip congenital lipodystrophy 2/seipin plays a key role in adipocyte differentiation. Endocrinology. 2009;150(10):4552–4561.
    View this article via: PubMed CrossRef Google Scholar
91. Razani B, Lisanti MP. Caveolin-deficient mice: insights into caveolar function human disease. J Clin Invest. 2001;108(11):1553–1561.
    View this article via: JCI PubMed CrossRef Google Scholar
92. Cohen AW, et al. Role of caveolin-1 in the modulation of lipolysis and lipid droplet formation. Diabetes. 2004;53(5):1261–1270.
    View this article via: PubMed CrossRef Google Scholar
93. Hayashi YK, et al. Human PTRF mutations cause secondary deficiency of caveolins resulting in muscular dystrophy with generalized lipodystrophy. J Clin Invest. 2009;119(9):2623–2633.
    View this article via: JCI PubMed CrossRef Google Scholar
94. Liu L, Pilch PF. A critical role of cavin (polymerase I and transcript release factor) in caveolae formation and organization. J Biol Chem. 2008;283(7):4314–4322.
    View this article via: PubMed CrossRef Google Scholar
95. Perez-Diaz S, et al. Polymerase I and transcript release factor (PTRF) regulates adipocyte differentiation and determines adipose tissue expandability. FASEB J. 2014;28(8):3769–3779.
    View this article via: PubMed CrossRef Google Scholar
96. Melvin A, et al. Recent developments in lipodystrophy. Curr Opin Lipidol. 2019;30(4):284–290.
    View this article via: PubMed CrossRef Google Scholar
97. Bagias C, et al. Familial partial lipodystrophy (fpld): recent insights. Diabetes Metab Syndr Obes. 2020;13(FPLD):1531–1544.
    View this article via: PubMed Google Scholar
98. Hussain I, Garg A. Lipodystrophy syndromes. Endocrinol Metab Clin North Am. 2016;45(4):783–797.
    View this article via: PubMed CrossRef Google Scholar
99. Guillín-Amarelle C, et al. Type 1 familial partial lipodystrophy: understanding the Köbberling syndrome. Endocrine. 2016;54(2):411–421.
    View this article via: PubMed CrossRef Google Scholar
100. Lotta LA, et al. Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance. Nat Genet. 2017;49(1):17–26.
     View this article via: PubMed CrossRef Google Scholar
101. Agarwal AK, et al. Genetic basis of congenital generalized lipodystrophy. Int J Obes Relat Metab Disord. 2004;28(2):336–339.
     View this article via: PubMed CrossRef Google Scholar
102. Araujo-Vilar D, et al. Site-dependent differences in both prelamin A and adipogenic genes in subcutaneous adipose tissue of patients with type 2 familial partial lipodystrophy. J Med Genet. 2009;46(1):40–48.
     View this article via: PubMed Google Scholar
103. Capanni C, et al. Altered pre-lamin A processing is a common mechanism leading to lipodystrophy. Hum Mol Genet. 2005;14(11):1489–1502.
     View this article via: PubMed CrossRef Google Scholar
104. Lloyd DJ, et al. A novel interaction between lamin A and SREBP1: implications for partial lipodystrophy and other laminopathies. Hum Mol Genet. 2002;11(7):769–777.
     View this article via: PubMed CrossRef Google Scholar
105. Resende ATP, et al. Phenotypic diversity and glucocorticoid sensitivity in patients with familial partial lipodystrophy type 2. Clin Endocrinol (Oxf). 2019;91(1):94–103.
     View this article via: PubMed Google Scholar
106. Savage DB, et al. Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes. 2003;52(4):910–917.
     View this article via: PubMed CrossRef Google Scholar
107. Chen RX, et al. The renal manifestations of type 4 familial partial lipodystrophy: a case report and review of literature. BMC Nephrol. 2018;19(1):111.
     View this article via: PubMed CrossRef Google Scholar
108. Rubio-Cabezas O, et al. Partial lipodystrophy and insulin resistant diabetes in a patient with a homozygous nonsense mutation in CIDEC. EMBO Mol Med. 2009;1(5):280–287.
     View this article via: PubMed CrossRef Google Scholar
109. Li F, et al. Cell death-inducing DFF45-like effector, a lipid droplet-associated protein, might be involved in the differentiation of human adipocytes. FEBS J. 2010;277(20):4173–4183.
     View this article via: PubMed CrossRef Google Scholar
110. Albert JS, et al. Null mutation in hormone-sensitive lipase gene and risk of type 2 diabetes. N Engl J Med. 2014;370(24):2307–2315.
     View this article via: PubMed CrossRef Google Scholar
111. Agarwal AK, et al. Zinc metalloproteinase, ZMPSTE24, is mutated in mandibuloacral dysplasia. Hum Mol Genet. 2003;12(16):1995–2001.
     View this article via: PubMed CrossRef Google Scholar
112. Simha V, et al. Genetic and phenotypic heterogeneity in patients with mandibuloacral dysplasia-associated lipodystrophy. J Clin Endocrinol Metab. 2003;88(6):2821–2824.
     View this article via: PubMed CrossRef Google Scholar
113. Simha V, Garg A. Body fat distribution and metabolic derangements in patients with familial partial lipodystrophy associated with mandibuloacral dysplasia. J Clin Endocrinol Metab. 2002;87(2):776–785.
     View this article via: PubMed CrossRef Google Scholar
114. Winnay JN, et al. PI3-kinase mutation linked to insulin and growth factor resistance in vivo. J Clin Invest. 2016;126(4):1401–1412.
     View this article via: JCI PubMed CrossRef Google Scholar
115. Yu J, et al. Regulation of the p85/p110 phosphatidylinositol 3’-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit. Mol Cell Biol. 1998;18(3):1379–1387.
     View this article via: PubMed CrossRef Google Scholar
116. Misra A, Garg A. Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature. Medicine (Baltimore). 2003;82(2):129–146.
     View this article via: PubMed CrossRef Google Scholar
117. Haque WA, et al. Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab. 2002;87(5):2395.
     View this article via: PubMed CrossRef Google Scholar
118. Pope E, et al. Childhood acquired lipodystrophy: a retrospective study. J Am Acad Dermatol. 2006;55(6):947–950.
     View this article via: PubMed CrossRef Google Scholar
119. Billings JK, et al. Lipoatrophic panniculitis: a possible autoimmune inflammatory disease of fat. Report of three cases. Arch Dermatol. 1987;123(12):1662–1666.
     View this article via: PubMed Google Scholar
120. Corvillo F, et al. Autoantibodies against perilipin 1 as a cause of acquired generalized lipodystrophy. Front Immunol. 2018;9:2142.
     View this article via: PubMed Google Scholar
121. Falcao CK, et al. Acquired lipodystrophy associated with nivolumab in a patient with advanced renal cell carcinoma. J Clin Endocrinol Metab. 2019;104(8):3245–3248.
     View this article via: PubMed CrossRef Google Scholar
122. Jehl A, et al. Acquired generalized lipodystrophy: a new cause of anti-PD-1 immune-related diabetes. Diabetes Care. 2019;42(10):2008–2010.
     View this article via: PubMed CrossRef Google Scholar
123. Bingham A, et al. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Medicine (Baltimore). 2008;87(2):70–86.
     View this article via: PubMed CrossRef Google Scholar
124. Fève B. Adipogenesis: cellular and molecular aspects. Best Pract Res Clin Endocrinol Metab. 2005;19(4):483–499.
     View this article via: PubMed CrossRef Google Scholar
125. Fischer-Posovszky P, et al. Role of CD95-mediated adipocyte loss in autoimmune lipodystrophy. J Clin Endocrinol Metab. 2006;91(3):1129–1135.
     View this article via: PubMed CrossRef Google Scholar
126. Corvillo F, Akinci B. An overview of lipodystrophy and the role of the complement system. Mol Immunol. 2019;112:223–232.
     View this article via: PubMed CrossRef Google Scholar
127. Oliveira J, et al. Barraquer-Simons syndrome: a rare form of acquired lipodystrophy. BMC Res Notes. 2016;9:175.
     View this article via: PubMed Google Scholar
128. Misra A, et al. Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature. Medicine (Baltimore). 2004;83(1):18–34.
     View this article via: PubMed CrossRef Google Scholar
129. Garg A. Lipodystrophies. Am J Med. 2000;108(2):143–152.
     View this article via: PubMed CrossRef Google Scholar
130. Mantzoros CS, Flier JS. Insulin resistance: the clinical spectrum. Adv Endocrinol Metab. 1995;6:193–232.
     View this article via: PubMed Google Scholar
131. Chen D, et al. Clinical review 153: Lipodystrophy in human immunodeficiency virus-infected patients. J Clin Endocrinol Metab. 2002;87(11):4845–4856.
     View this article via: PubMed CrossRef Google Scholar
132. Mallewa JE, et al. HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options. J Antimicrob Chemother. 2008;62(4):648–660.
     View this article via: PubMed CrossRef Google Scholar
133. Caron M, et al. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes. 2001;50(6):1378–1388.
     View this article via: PubMed CrossRef Google Scholar
134. Dowell P, et al. Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors. J Biol Chem. 2000;275(52):41325–41332.
     View this article via: PubMed CrossRef Google Scholar
135. Shlay JC, et al. The effect of individual antiretroviral drugs on body composition in HIV-infected persons initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2009;51(3):298–304.
     View this article via: PubMed CrossRef Google Scholar
136. Bastard JP, et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet. 2002;359(9311):1026–1031.
     View this article via: PubMed CrossRef Google Scholar
137. Shrivastav S, et al. Human immunodeficiency virus (HIV)-1 viral protein R suppresses transcriptional activity of peroxisome proliferator-activated receptor γ and inhibits adipocyte differentiation: implications for HIV-associated lipodystrophy. Mol Endocrinol. 2008;22(2):234–247.
     View this article via: PubMed CrossRef Google Scholar
138. Ranade K, et al. Genetic analysis implicates resistin in HIV lipodystrophy. AIDS. 2008;22(13):1561–1568.
     View this article via: PubMed CrossRef Google Scholar
139. Castilhos JK, et al. Polymorphisms in adiponectin receptor genes are associated with lipodystrophy-related phenotypes in HIV-infected patients receiving antiretroviral therapy. HIV Med. 2015;16(8):494–501.
     View this article via: PubMed CrossRef Google Scholar
140. Sweeney LL, et al. The role of adipokines in relation to HIV lipodystrophy. AIDS. 2007;21(8):895–904.
     View this article via: PubMed CrossRef Google Scholar
141. Nagy GS, et al. Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin. Clin Infect Dis. 2003;36(6):795–802.
     View this article via: PubMed CrossRef Google Scholar
142. Srinivasa S, Grinspoon SK. Metabolic and body composition effects of newer antiretrovirals in HIV-infected patients. Eur J Endocrinol. 2014;170(5):R185–R202.
     View this article via: PubMed CrossRef Google Scholar
143. Depairon M, et al. Premature atherosclerosis in HIV-infected individuals—focus on protease inhibitor therapy. AIDS. 2001;15(3):329–334.
     View this article via: PubMed CrossRef Google Scholar
144. Seminari E, et al. Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors. Atherosclerosis. 2002;162(2):433–438.
     View this article via: PubMed CrossRef Google Scholar
145. Soudan B, et al. Extreme subcutaneous insulin resistance: a misunderstood syndrome. Diabetes Metab. 2003;29(5):539–546.
     View this article via: PubMed CrossRef Google Scholar
146. Agarwal S, et al. Use of inhaled insulin in a patient with subcutaneous insulin resistance syndrome: a rare condition. AACE Clin Case Rep. 2019;5(3):e187–e191.
     View this article via: PubMed CrossRef Google Scholar
147. Jassam N, et al. Analytical and clinical challenges in a patient with concurrent type 1 diabetes, subcutaneous insulin resistance and insulin autoimmune syndrome. Endocrinol Diabetes Metab Case Rep. 2014;2014:130086.
     View this article via: PubMed Google Scholar
148. Magkos F, et al. Management of the metabolic syndrome and type 2 diabetes through lifestyle modification. Annu Rev Nutr. 2009;29:223–256.
     View this article via: PubMed CrossRef Google Scholar
149. Grundy SM, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735–2752.
     View this article via: PubMed CrossRef Google Scholar
150. Lloyd-Jones DM, et al. Consistently stable or decreased body mass index in young adulthood and longitudinal changes in metabolic syndrome components: the Coronary Artery Risk Development in Young Adults Study. Circulation. 2007;115(8):1004–1011.
     View this article via: PubMed CrossRef Google Scholar
151. Esposito K, et al. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA. 2004;292(12):1440–1446.
     View this article via: PubMed CrossRef Google Scholar
152. Papadaki A, et al. The effect of the Mediterranean diet on metabolic health: a systematic review and meta-analysis of controlled trials in adults. Nutrients. 2020;12(11):3342.
     View this article via: PubMed CrossRef Google Scholar
153. Papendieck L, Araujo MB. Clinical outcome in a series of pediatric patients with congenital generalized lipodystrophies treated with dietary therapy. J Pediatr Endocrinol Metab. 2018;31(1):77–83.
     View this article via: PubMed CrossRef Google Scholar
154. Lindegaard B, et al. The effect of strength and endurance training on insulin sensitivity and fat distribution in human immunodeficiency virus-infected patients with lipodystrophy. J Clin Endocrinol Metab. 2008;93(10):3860–3869.
     View this article via: PubMed CrossRef Google Scholar
155. Akinci G, et al. Spectrum of clinical manifestations in two young Turkish patients with congenital generalized lipodystrophy type 4. Eur J Med Genet. 2016;59(6-7):320–324.
     View this article via: PubMed CrossRef Google Scholar
156. Moore MM, et al. Treatment of diabetic ketoacidosis with intravenous U-500 insulin in a patient with Rabson-Mendenhall syndrome: a case report. J Pharm Pract. 2017;30(4):468–475.
     View this article via: PubMed CrossRef Google Scholar
157. Semple RK, et al. What is the best management strategy for patients with severe insulin resistance? Clin Endocrinol (Oxf). 2010;73(3):286–290.
     View this article via: PubMed CrossRef Google Scholar
158. Lane WS, et al. High-dose insulin therapy: is it time for U-500 insulin? Endocr Pract. 2009;15(1):71–79.
     View this article via: PubMed CrossRef Google Scholar
159. Lamos EM, et al. Concentrated insulins: the new basal insulins. Ther Clin Risk Manag. 2016;12:389–400.
     View this article via: PubMed Google Scholar
160. Plamper M, et al. Mecasermin in insulin receptor-related severe insulin resistance syndromes: case report and review of the literature. Int J Mol Sci. 2018;19(5):1268.
     View this article via: PubMed CrossRef Google Scholar
161. Kawashima Y, et al. Leprechaunism (Donohue syndrome): a case bearing novel compound heterozygous mutations in the insulin receptor gene. Endocr J. 2013;60(1):107–112.
     View this article via: PubMed CrossRef Google Scholar
162. Weber DR, et al. Continuous subcutaneous IGF-1 therapy via insulin pump in a patient with Donohue syndrome. J Pediatr Endocrinol Metab. 2014;27(11-12):1237–1241.
     View this article via: PubMed Google Scholar
163. LeRoith D, Yakar S. Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1. Nat Clin Pract Endocrinol Metab. 2007;3(3):302–310.
     View this article via: PubMed CrossRef Google Scholar
164. Kohli R, et al. A randomized placebo-controlled trial of metformin for the treatment of HIV lipodystrophy. HIV Med. 2007;8(7):420–426.
     View this article via: PubMed CrossRef Google Scholar
165. Agostini M, et al. A pharmacogenetic approach to the treatment of patients with PPARG mutations. Diabetes. 2018;67(6):1086–1092.
     View this article via: PubMed CrossRef Google Scholar
166. Moreau F, et al. Efficacy of pioglitazone in familial partial lipodystrophy of the Dunnigan type: a case report. Diabetes Metab. 2007;33(5):385–389.
     View this article via: PubMed CrossRef Google Scholar
167. Caldwell SH. Efficacy and safety of troglitazone for lipodystrophy syndromes. Ann Intern Med. 2001;134(10):1008.
168. Simha V, Garg A. Inherited lipodystrophies and hypertriglyceridemia. Curr Opin Lipidol. 2009;20(4):300–308.
     View this article via: PubMed CrossRef Google Scholar
169. Shah AS, Wilson DP. Primary hypertriglyceridemia in children and adolescents. J Clin Lipidol. 2015;9(5 suppl):S20–S28.
     View this article via: PubMed Google Scholar
170. Ray KK, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507–1519.
     View this article via: PubMed CrossRef Google Scholar
171. Ray KK, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380(11):1022–1032.
     View this article via: PubMed CrossRef Google Scholar
172. Witztum JL, et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N Engl J Med. 2019;381(6):531–542.
     View this article via: PubMed CrossRef Google Scholar
173. Fogacci F, et al. Efficacy and safety of volanesorsen (ISIS 304801): the evidence from phase 2 and 3 clinical trials. Curr Atheroscler Rep. 2020;22(5):18.
     View this article via: PubMed CrossRef Google Scholar
174. The BROADEN study: a study of volanesorsen (formerly ISIS-APOCIIIRx) in patients with familial partial lipodystrophy. NCT02527343. Updated January 10, 2020. Accessed January 11, 2021.
175. Ahmad Z, et al. Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia. Circulation. 2019;140(6):470–486.
     View this article via: PubMed CrossRef Google Scholar
176. Graham MJ, et al. Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides. N Engl J Med. 2017;377(3):222–232.
     View this article via: PubMed CrossRef Google Scholar
177. Study of gemcabene in adults with FPLD. NCT03508687. Updated August 17, 2020. Accessed December 25, 2020.
178. US Food and Drug Administration. Highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125390s000lbl.pdf February 2014. Accessed December 13, 2020.
179. Chan JL, et al. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy. Endocr Pract. 2011;17(6):922–932.
     View this article via: PubMed CrossRef Google Scholar
180. Oral EA, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med. 2002;346(8):570–578.
     View this article via: PubMed CrossRef Google Scholar
181. Zadeh ES, et al. The liver diseases of lipodystrophy: the long-term effect of leptin treatment. J Hepatol. 2013;59(1):131–137.
     View this article via: PubMed CrossRef Google Scholar
182. Petersen KF, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest. 2002;109(10):1345–1350.
     View this article via: JCI PubMed CrossRef Google Scholar
183. Simha V, et al. Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety. J Clin Endocrinol Metab. 2012;97(3):785–792.
     View this article via: PubMed CrossRef Google Scholar
184. Brown RJ, et al. Effects of metreleptin in pediatric patients with lipodystrophy. J Clin Endocrinol Metab. 2017;102(5):1511–1519.
     View this article via: PubMed CrossRef Google Scholar
185. Chan JL, et al. Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy. Clin Endocrinol (Oxf). 2016;85(1):137–149.
     View this article via: PubMed CrossRef Google Scholar
186. Brown RJ, et al. Lymphoma in acquired generalized lipodystrophy. Leuk Lymphoma. 2016;57(1):45–50.
     View this article via: PubMed CrossRef Google Scholar
187. Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359–2370.
     View this article via: PubMed CrossRef Google Scholar
188. Lo J, et al. Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial. JAMA. 2008;300(5):509–519.
     View this article via: PubMed CrossRef Google Scholar
189. Falutz J, et al. A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS. 2005;19(12):1279–1287.
     View this article via: PubMed CrossRef Google Scholar
190. Falutz J, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010;53(3):311–322.
     View this article via: PubMed CrossRef Google Scholar
191. Falutz J, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291–4304.
     View this article via: PubMed CrossRef Google Scholar
192. Iseri K, et al. Rituximab for the treatment of type B insulin resistance syndrome: a case report and review of the literature. Diabet Med. 2017;34(12):1788–1791.
     View this article via: PubMed CrossRef Google Scholar
193. Viswanathan L, Sirisena I. Immunosuppressive therapy in treatment of refractory hypoglycemia in type B insulin resistance: a case report. J Endocr Soc. 2017;1(12):1435–1439.
     View this article via: PubMed CrossRef Google Scholar